$37.63
0.29% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US8688731004
Symbol
SRDX

Surmodics Inc Stock News

Neutral
Business Wire
4 days ago
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium in Washing...
Neutral
Business Wire
about one month ago
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System is indicated for the non-surgical removal of thrombi and emboli from the peripheral arter...
Neutral
Business Wire
5 months ago
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-nego...
Neutral
Accesswire
5 months ago
NEW ORLEANS, LA / ACCESSWIRE / May 30, 2024 / Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Neutral
PRNewsWire
5 months ago
NEW YORK , May 29, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Surmodics, Inc. (NASDAQ: SRDX) and its board of directors concerning the proposed acquisition of the company by GTCR. Stockholders will receive $43.00 for each share of Surmodics stock that they hold.
Positive
Investors Business Daily
5 months ago
Merck and Surmodics announced big takeover deals Wednesday, but Merck stock remained at a standstill as Surmodics stock rocketed.
Neutral
PRNewsWire
5 months ago
MILWAUKEE , May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Surmodics (Nasdaq: SRDX) for possible breaches of fiduciary duty and other violations of law in its transaction with GTCR. Click here to learn how to join the https://www.ademilaw.com/case/surmodics-inc or call Guri Ademi toll-free at 866-264-3995.
Neutral
Business Wire
5 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Surmodics, Inc. (NASDAQ: SRDX) to GTCR for $43.00 per share in cash is fair to Surmodics shareholders. Halper Sadeh encourages Surmodics shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ha...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today